DescriptionSources: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000920/WC500047922.pdfCurator's Comment: description was created based on several sources, including
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000920/WC500047919.pdf
http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/11/WC500014528.pdf
https://www.medicines.org.uk/emc/medicine/24235
https://www.ncbi.nlm.nih.gov/pubmed/12537931
Sources: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000920/WC500047922.pdf
Curator's Comment: description was created based on several sources, including
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000920/WC500047919.pdf
http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/11/WC500014528.pdf
https://www.medicines.org.uk/emc/medicine/24235
https://www.ncbi.nlm.nih.gov/pubmed/12537931
Tocophersolan (Vedrop, tocofersolan) or d-alpha-Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS) is a watersoluble derivative of the natural active (d-alpha) isomer of vitamin E. The active constituent of the medicinal product is essentially vitamin E (alpha tocopherol). Chronic congenital or hereditary cholestasis is a clinical condition where vitamin E deficiency results from an impaired bile secretion. Decreased intestinal absorption observed in chronic congenital or hereditary cholestatic patients is due to decreased bile secretion and the resulting decrease in intestinal cellular absorption. As a result, fatsoluble vitamins (i.e. vit. E) are not absorbed properly and deficiency can occur. Tocophersolan (Vedrop) is used to treat or prevent vitamin E deficiency (low vitamin E levels). It is used in children up to the age of 18 years who have congenital or hereditary chronic cholestasis and who cannot absorb vitamin E from the gut. Tocophersolan (Tocofersolan) can be absorbed from the gut in children who have difficulty absorbing fats and vitamin E from the diet. This can increase vitamin E levels in the blood and help to prevent neurological deterioration (problems in the nervous system) due to vitamin E deficiency. No treatment-related findings were reported, as all clinical observations and findings at autopsy were similar in treatment and control groups. In many of the studies, the LD50 was not
determined as tocofersolan was well tolerated.
CNS Activity
Sources: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000920/WC500047922.pdf
Curator's Comment: Neurological symptoms were either improved or stabilized in 96% of patients with chronic congenital or hereditary cholestasis (pages 19-20)
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0016209 Sources: http://www.ncbi.nlm.nih.gov/pubmed/8387948 |
|||
Target ID: WP408 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Vedrop Approved UseTocophersolan (Vedrop) is used to treat or prevent vitamin E deficiency (low vitamin E levels). The recommended total daily dose in paediatric patients suffering from congenital chronic cholestasis or hereditary chronic cholestasis is 0.34 ml/kg/day (17 mg/kg of d-alpha-tocopherol in the form of tocofersolan). The dose should be prescribed in ml. |
|||
Palliative | Vedrop Approved UseTocophersolan (Vedrop) is used to treat or prevent vitamin E deficiency (low vitamin E levels). The recommended total daily dose in paediatric patients suffering from congenital chronic cholestasis or hereditary chronic cholestasis is 0.34 ml/kg/day (17 mg/kg of d-alpha-tocopherol in the form of tocofersolan). The dose should be prescribed in ml. |
|||
Palliative | Vedrop Approved UseUnknown |
|||
Palliative | Vedrop Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Treatment of cholestatic children with water-soluble vitamin E (alpha-tocopheryl polyethylene glycol succinate): effects on serum vitamin E, lipid peroxides, and polyunsaturated fatty acids. | 1997 Feb |
|
Final report on the safety assessment of Tocopherol, Tocopheryl Acetate, Tocopheryl Linoleate, Tocopheryl Linoleate/Oleate, Tocopheryl Nicotinate, Tocopheryl Succinate, Dioleyl Tocopheryl Methylsilanol, Potassium Ascorbyl Tocopheryl Phosphate, and Tocophersolan. | 2002 |
|
Bioavailability of oral vitamin E formulations in adult volunteers and children with chronic cholestasis or cystic fibrosis. | 2009 Oct |
|
Effect of hydrosoluble vitamin E on erythrocyte membrane lipid composition in patients with advanced cirrhosis: An open-label pilot trial. | 2015 Aug |
|
Oral Tocofersolan Corrects or Prevents Vitamin E Deficiency in Children With Chronic Cholestasis. | 2016 Dec |
|
Efficacy of two vitamin E formulations in patients with abetalipoproteinemia and chylomicron retention disease. | 2018 Sep |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000920/WC500047919.pdf
Curator's Comment: Tocophersolan (Vedrop) is given with or without water. This dose should be adjusted depending on the amount of vitamin E in the child’s blood. This should be checked regularly.
The recommended total daily dose in paediatric patients suffering from congenital chronic cholestasis or hereditary chronic cholestasis is 0.34 ml/kg/day (17 mg/kg of d-alpha-tocopherol in the form of tocofersolan). The dose should be prescribed in ml.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000920/WC500047922.pdf
Curator's Comment: page 8
In vitro studies using fibroblasts, enterocytes and Caco-2 cells conclude that Tocophersolan (tocofersolan) is taken up as the intact molecule and undergoes a slow hydrolysis reaction, intracellularly, to give PEG 1000 and Vitamin E (d-α tocopherol).
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
468414
Created by
admin on Sat Dec 16 03:42:45 GMT 2023 , Edited by admin on Sat Dec 16 03:42:45 GMT 2023
|
||
|
FDA ORPHAN DRUG |
22687
Created by
admin on Sat Dec 16 03:42:45 GMT 2023 , Edited by admin on Sat Dec 16 03:42:45 GMT 2023
|
||
|
WHO-ATC |
A11HA08
Created by
admin on Sat Dec 16 03:42:45 GMT 2023 , Edited by admin on Sat Dec 16 03:42:45 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
VEDROP (AUTHORIZED: CHOLESTASIS)
Created by
admin on Sat Dec 16 03:42:45 GMT 2023 , Edited by admin on Sat Dec 16 03:42:45 GMT 2023
|
||
|
NCI_THESAURUS |
C275
Created by
admin on Sat Dec 16 03:42:45 GMT 2023 , Edited by admin on Sat Dec 16 03:42:45 GMT 2023
|
||
|
WHO-VATC |
QA11HA08
Created by
admin on Sat Dec 16 03:42:45 GMT 2023 , Edited by admin on Sat Dec 16 03:42:45 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1706
Created by
admin on Sat Dec 16 03:42:45 GMT 2023 , Edited by admin on Sat Dec 16 03:42:45 GMT 2023
|
PRIMARY | |||
|
CHEMBL2108106
Created by
admin on Sat Dec 16 03:42:45 GMT 2023 , Edited by admin on Sat Dec 16 03:42:45 GMT 2023
|
PRIMARY | |||
|
C67044
Created by
admin on Sat Dec 16 03:42:45 GMT 2023 , Edited by admin on Sat Dec 16 03:42:45 GMT 2023
|
PRIMARY | |||
|
CHEMBL2108812
Created by
admin on Sat Dec 16 03:42:45 GMT 2023 , Edited by admin on Sat Dec 16 03:42:45 GMT 2023
|
PRIMARY | |||
|
SUB31955
Created by
admin on Sat Dec 16 03:42:45 GMT 2023 , Edited by admin on Sat Dec 16 03:42:45 GMT 2023
|
PRIMARY | |||
|
TOCOFERSOLAN
Created by
admin on Sat Dec 16 03:42:45 GMT 2023 , Edited by admin on Sat Dec 16 03:42:45 GMT 2023
|
PRIMARY | |||
|
100000124318
Created by
admin on Sat Dec 16 03:42:45 GMT 2023 , Edited by admin on Sat Dec 16 03:42:45 GMT 2023
|
PRIMARY | |||
|
C014225
Created by
admin on Sat Dec 16 03:42:45 GMT 2023 , Edited by admin on Sat Dec 16 03:42:45 GMT 2023
|
PRIMARY | |||
|
9002-96-4
Created by
admin on Sat Dec 16 03:42:45 GMT 2023 , Edited by admin on Sat Dec 16 03:42:45 GMT 2023
|
PRIMARY | |||
|
O03S90U1F2
Created by
admin on Sat Dec 16 03:42:45 GMT 2023 , Edited by admin on Sat Dec 16 03:42:45 GMT 2023
|
PRIMARY | |||
|
DB11635
Created by
admin on Sat Dec 16 03:42:45 GMT 2023 , Edited by admin on Sat Dec 16 03:42:45 GMT 2023
|
PRIMARY | |||
|
159151
Created by
admin on Sat Dec 16 03:42:45 GMT 2023 , Edited by admin on Sat Dec 16 03:42:45 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID1048623
Created by
admin on Sat Dec 16 03:42:45 GMT 2023 , Edited by admin on Sat Dec 16 03:42:45 GMT 2023
|
PRIMARY | |||
|
O03S90U1F2
Created by
admin on Sat Dec 16 03:42:45 GMT 2023 , Edited by admin on Sat Dec 16 03:42:45 GMT 2023
|
PRIMARY | |||
|
4280
Created by
admin on Sat Dec 16 03:42:45 GMT 2023 , Edited by admin on Sat Dec 16 03:42:45 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD